Deutetrabenazine
Choreatic Disease
Teva Branded Pharmaceutical Products R&D LLCSmall moleculePhase 4 / ApprovedActive
BBB
76/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 64/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Choreatic Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Atomoxetine University of Iowa | Phase 2 | B |
Amantadine Novartis Pharmaceuticals | Phase 2 | B |
Risperidone University of Rochester | Phase 2 | B |
Citalopram University of Iowa | Phase 2 | B |
1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)- Novartis Pharmaceuticals | Phase 2 | CCC |
Same molecule, other indications
Deutetrabenazine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →